The stock of Calithera Biosciences Inc (NASDAQ:CALA) is a huge mover today! About 350,334 shares traded hands or 191.55% up from the average. Calithera Biosciences Inc (NASDAQ:CALA) has declined 45.29% since February 29, 2016 and is downtrending. It has underperformed by 57.50% the S&P500.
The move comes after 9 months positive chart setup for the $70.59M company. It was reported on Oct, 3 by Barchart.com. We have $6.75 PT which if reached, will make NASDAQ:CALA worth $69.18 million more.
Analysts await Calithera Biosciences Inc (NASDAQ:CALA) to report earnings on November, 14. They expect $-0.47 EPS, up 4.08% or $0.02 from last year’s $-0.49 per share. After $-0.55 actual EPS reported by Calithera Biosciences Inc for the previous quarter, Wall Street now forecasts -14.55% EPS growth.
Calithera Biosciences Inc (NASDAQ:CALA) Ratings Coverage
Out of 3 analysts covering Calithera Biosciences (NASDAQ:CALA), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Calithera Biosciences has been the topic of 3 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The stock of Calithera Biosciences Inc (NASDAQ:CALA) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The firm has “Buy” rating by Citigroup given on Friday, July 24.
According to Zacks Investment Research, “Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company’s lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California.”
Insitutional Activity: The institutional sentiment decreased to 0.47 in Q2 2016. Its down 0.57, from 1.04 in 2016Q1. The ratio dived, as 16 funds sold all Calithera Biosciences Inc shares owned while 18 reduced positions. 9 funds bought stakes while 7 increased positions. They now own 7.04 million shares or 18.29% less from 8.61 million shares in 2016Q1.
Bvf Il has 121,400 shares for 0.1% of their US portfolio. D E Shaw And Company has invested 0% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA). Deutsche Fincl Bank Ag has invested 0% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA). Amici Ltd Liability Corp holds 0% or 6,360 shares in its portfolio. Fincl Bank Of America Corporation De holds 0% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA) for 3,598 shares. Manufacturers Life Insur Com The last reported 0% of its portfolio in the stock. National Bank Of New York Mellon has 0% invested in the company for 19,879 shares. Fmr Ltd Com accumulated 0% or 2.00 million shares. Franklin Street Advisors Nc accumulated 84,300 shares or 0.06% of the stock. First Eagle Inv Limited holds 0% or 205,369 shares in its portfolio. Gsa Capital Partners Ltd Liability Partnership has 43,800 shares for 0.01% of their US portfolio. Howland Lc, a Massachusetts-based fund reported 12,000 shares. Barclays Pcl has invested 0% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA). Jpmorgan Chase &, a New York-based fund reported 1,061 shares. California Public Employees Retirement last reported 14,100 shares in the company.
More notable recent Calithera Biosciences Inc (NASDAQ:CALA) news were published by: Prnewswire.com which released: “ProTrials Research, Inc. Selected by Calithera Biosciences, Inc. for Early …” on July 25, 2016, also Quotes.Wsj.com with their article: “News Calithera Biosciences Inc.CALA” published on February 17, 2011, Globenewswire.com published: “Calithera Biosciences to Present at the Leerink Partners Roundtable Series …” on September 22, 2016. More interesting news about Calithera Biosciences Inc (NASDAQ:CALA) were released by: Finance.Yahoo.com and their article: “Calithera Biosciences to Present at Two Healthcare Conferences in September” published on July 25, 2016 as well as Zacks.com‘s news article titled: “Calithera Biosciences, Inc. (CALA) in Focus: Stock Soars 29.9%” with publication date: October 22, 2014.
CALA Company Profile
Calithera Biosciences, Inc., incorporated on March 9, 2010, is a clinical-stage pharmaceutical company. The Firm focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. The Firm is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company’s lead product candidate, CB-839, is a critical enzyme in tumor cells. The Company’s other product candidate, CB-1158, which is an enzyme that depletes the amino acid arginine, a key metabolic nutrient for T-cells. The Company’s lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a therapeutic agent for the target.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.